Protara Therapeutics, Inc. (TARA) Form 424B5 — May 28, 2026
Protara Therapeutics (TARA) filed a prospectus supplement registering up to $100 million of common stock for sale via an at-the-market (ATM) facility with TD Cowen. The company intends to use net proceeds to fund clinical development of its lead programs, TARA-002 for bladder cancer and lymphatic malformations, and IV Choline Chloride for patients on parenteral support. As of March 31, 2026, Protara reported $181.2 million in net tangible book value, or $3.29 per share.
Key figures
- Cash Position
- 181200000
- Gross Proceeds
- 100000000
- Offering Price
- 5.21
- Shares Outstanding
- 55055582
- Agent fee percent
- 3
- Shelf capacity total
- 300000000
- Adjusted ntbv per share
- 3.74
- Dilution per share new investors
- 1.47
- Net tangible book value per share
- 3.29
Price after filing
Close on the filing date to close N calendar days later (from $4.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.